Post-marketing Carcinogenicity Study of Bupropion.

Trial Profile

Post-marketing Carcinogenicity Study of Bupropion.

Phase of Trial: Phase IV

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Antidepressants; Bupropion; Serotonin uptake inhibitors; Tricyclic antidepressants
  • Indications Depressive disorders
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Feb 2011 Actual end date (Mar 2010) added as reported by
    • 09 Feb 2011 Status changed from active, no longer recruiting to completed as reported by
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top